Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Neuroscience >> Neurology process >> Neurogenesis
Overview
Product name
Anti-RUNX1 / AML1 antibody
See all RUNX1 / AML1 products (14) ...
Description
Mouse monoclonal to RUNX1 / AML1
Tested applications
WB, IHC-P, ICC/IFmore details
Cross reactivity
Reacts with
Human
Immunogen
Recombinant fragment, corresponding to amino acids 210-311 of Human RUNX1 / AML1
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: None
PBS, pH 7.2
Concentration
Concentration information loading...
Purity
Protein G purified
Clonality
Monoclonal
Isotype
IgG2b
Light chain type
kappa
Research areas
Developmental Biology >> Organogenesis >> Hematopoietic system development
Stem Cells >> Hematopoietic Progenitors >> Hemangioblast
Cancer >> Oncoproteins/suppressors >> Oncoproteins >> Transcription factors
Epigenetics and Nuclear Signaling >> Chromatin Binding Proteins >> DNA / RNA binding
Stem Cells >> Hematopoietic Progenitors >> Intracellular Molecules
Epigenetics and Nuclear Signaling >> Transcription >> Other factors
Neuroscience >> Neurology process >> Neurogenesis
Applications
Show applications key
Our Abpromise guarantee covers the use of ab54869 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use a concentration of 1 - 5 µg/ml.Predicted molecular weight: 49 kDa.
IHC-P: Use a concentration of 3 µg/ml
ICC/IF: Use a concentration of 10 µg/ml
Target
Function
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.
Tissue specificity
Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
Involvement in disease
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.
Sequence similarities
Contains 1 Runt domain.
Domain
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.
Post-translational
modifications
Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
Methylated.
Cellular localization
Nucleus.
Target information above from: UniProt accessionQ01196
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- Acute myeloid leukemia 1 antibody
- Acute myeloid leukemia 1 protein antibody
- alpha subunit core binding factor antibody
see all
Database links
- Entrez Gene: 861 Human
- Omim: 151385 Human
- SwissProt: Q01196 Human
- Unigene: 149261 Human
- Unigene: 612648 Human
Anti-RUNX1 / AML1 antibody images:
IHC-P - RUNX1 / AML1 antibody (ab54869)
RUNX1 / AML1 antibody (ab54869) used in immunohistochemistry at 3ug/ml on formalin fixed and paraffin embedded human placenta.
Western blot - RUNX1 / AML1 antibody (ab54869)
RUNX1 / AML1 antibody (ab54869) at 1ug/lane + HeLa cell lysate at 25ug/lane.
Immunocytochemistry/ Immunofluorescence-RUNX1 / AML1 antibody(ab54869)
ab54869 at 10 ug/ml staining RUNX1 / AML1 in human Hela cells by Immunocytochemistry / Immunofluorescence.
References for Anti-RUNX1 / AML1 antibody (ab54869)
ab54869 has not yet been referenced specifically in any publications.
Publishing research using ab54869? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"